BCRX•benzinga•
BioCryst Pharmaceuticals Expects Full Year 2025 Total Revenue Of $560M-$575M Compared To Prior Guidance Of $540M-$560M And Consensus Of 545.31M, The Company Increased Its 2025 Outlook For Global Net Orladeyo Revenue To Between $535M-$550M, Previously $515
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 24, 2025 by benzinga